Fibrosarcoma - 21 Studies Found
| Completed | 
                                    : Imatinib in Dermatofibrosarcoma Protuberans (DFSP) : Dermatofibrosarcoma : 2005-07-20 : Drug: Imatinib (Glivec)  | 
                                
| Completed | 
                                    : Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans : Dermatofibrosarcoma Protuberans : 2005-10-20 : Drug: imatinib mesylate 400 mg orally twice a day for 10 - 14 days  | 
                                
| Terminated | 
                                    : Phase II Pazopanib Study in Advanced Dermatofibrosarcomas : Dermatofibrosarcomas of DARIER FERRAND(DFSP) : 2010-01-28 : Drug: Pazopanib Administration of pazopanib per os 800mg/ qd during 6 months until stable response accor  | 
                                
| Completed | 
                                    : Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans : 
 :  | 
                                
| Completed | 
                                    : Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans : Soft Tissue Neoplasms : 2005-09-12  | 
                                
| Completed | 
                                    : Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma : Sarcoma : 2004-06-10 : 
  | 
                                
| Completed | 
                                    : Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes : 
  | 
                                
| Completed | 
                                    : Spanish Registry of Mohs Surgery : 
  | 
                                
| Completed | 
                                    : To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors : 
 : Drug: nab-paclitaxel nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle  | 
                                
| Completed | 
                                    : AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma : 
  |